Invesco’s ALX Oncology ALXO Stock Holding History

Invesco’s Portfolio ALXO Stock Details ALXO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$310K	Buy	149,923 +138,943	+1,265%	+$249K	﹤0.01%	3431
2026 Q1	$22K	Buy	+10,980	New	+$20.9K	﹤0.01%	3724
2025 Q2	–	Sell	-73,836	Closed	-$46K	–	3766
2025 Q1	$46K	Buy	+73,836	New	+$88.6K	﹤0.01%	3704
2024 Q3	–	Sell	-10,290	Closed	-$62K	–	3756
2024 Q2	$62K	Buy	+10,290	New	+$127K	﹤0.01%	3800
2024 Q1	–	Sell	-385,232	Closed	-$5.74M	–	3863
2023 Q4	$5.74M	Buy	+385,232	New	+$3.65M	﹤0.01%	2167
2022 Q2	–	Sell	-643,487	Closed	-$10.9M	–	4037
2022 Q1	$10.9M	Buy	643,487 +13,565	+2%	+$232K	﹤0.01%	1915
2021 Q4	$13.5M	Buy	629,922 +115,107	+22%	+$4.96M	﹤0.01%	1816
2021 Q3	$38M	Buy	514,815 +507,399	+6,842%	+$33.8M	0.01%	1168
2021 Q2	$406K	Buy	7,416 +4,225	+132%	+$253K	﹤0.01%	3506
2021 Q1	$235K	Buy	+3,191	New	+$251K	﹤0.01%	3640

Other funds holding ALXO

RCM

RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return

venBio Partners San Francisco, California $519M AUM 339.42% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return

Blackstone Inc New York $32.9B AUM 23.66% 1-Year Est. Return

DCM

Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return

SCM

Silverarc Capital Management Boston, Massachusetts $962M AUM 524.64% 1-Year Est. Return

TCM

TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return

Invesco's ALXO Position: Q2 2026 in Review

Invesco increased its ALX Oncology (ALXO) stake by 1,265% in Q2 2026, buying an estimated $249K and bringing the position to 149,923 shares worth $310K. The position accounts for ﹤0.01% of the portfolio, ranked #3431.

Invesco first reported a position in ALXO in Q1 2021 and has held it in 10 quarters since. The position peaked at $38M in Q3 2021. 94 funds tracked by Wall St. Rank hold ALXO as of Q2 2026.

Invesco held 149,923 shares of ALX Oncology worth $310K as of Q2 2026.
Invesco bought 138,943 ALX Oncology shares in Q2 2026, an estimated $249K.
ALX Oncology made up ﹤0.01% of Invesco's portfolio in Q2 2026, its #3431 holding.
Invesco first reported a position in ALX Oncology in Q1 2021 and has held it in 10 quarters since.
Invesco's ALX Oncology position peaked at $38M in Q3 2021.
94 funds tracked by Wall St. Rank held ALX Oncology as of Q2 2026.

Based on Invesco's 13F filing for Q2 2026, filed 14 Aug 2026.